ReviewThe ocular surface2015
Novel Therapy to Treat Corneal Epithelial Defects: A Hypothesis with Growth Hormone.
Review in The ocular surface, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed.
- Self-assembling biomimetic peptide hydrogel regulates tissue homeostasis to promote repair of persistent corneal epithelial defects.Bioactive materials · 2026Article
- Management of ocular surface disease involving inflammation and persistent epithelial defects utilising various treatment modalities in the UK National Health Service (NHS).Eye (London, England) · 2026Article
- Advanced Glycation End-Products Contribute to Delayed Diabetic Corneal Epithelial Wound Healing via the TLR4 Signaling.Investigative ophthalmology & visual science · 2026Article
- Ferroptosis: A Novel Mechanism in Diabetic Keratopathy.Investigative ophthalmology & visual science · 2026Article
- Amniotic Membrane Transplantation versus Tarsorrhaphy for the Treatment of Persistent Corneal Epithelial Defects: A Comparative Study in a Tertiary Eye Care Facility in Riyadh, Saudi Arabia.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
- Rapid Pterygium Progression in a Child on Growth Hormone Therapy: A Case Report and Literature Review.Cureus · 2026Article
- Clinical evidence and critical review of mesenchymal stromal cells for corneal and ocular surface diseases.Stem cells (Dayton, Ohio) · 2025Review
- Use of femtosecond laser generated reactive oxygen species to manage inflammation and enhance wound healing after ocular trauma.Scientific reports · 2025Article
- Fatty Acid Desaturase 1 Knockdown Promotes Wound Healing and Functional Recovery of the Corneal Epithelium in Diabetes.Investigative ophthalmology & visual science · 2025Article
- Review
- Emerging Treatments for Persistent Corneal Epithelial Defects.Vision (Basel, Switzerland) · 2025Review
- Epigenetic ALYREF/UHRF1/RHOB Axis in Corneal Wound Healing and Implications for Epithelial Tumorigenesis.Investigative ophthalmology & visual science · 2025Article
- Novel full-thickness biomimetic corneal model for studying pathogenesis and treatment of diabetic keratopathy.Materials today. Bio · 2025Article
- Prevalence of Certain Corneal Conditions and their Demographic Risk Factors; Tehran Geriatric Eye Study.Archives of Iranian medicine · 2024Article
- Bone marrow mesenchymal stem cell-derived extracellular vesicles promote corneal epithelial repair and suppress apoptosis via modulation of Caspase-3 in vitro.FEBS open bio · 2024Article
- Topical insulin for refractory persistent corneal epithelial defects.Scientific reports · 2024Article
- Review
- Elucidating the mechanism of corneal epithelial cell repair: unraveling the impact of growth factors.Frontiers in medicine · 2024Review
- MiRNA 24-3p-rich exosomes functionalized DEGMA-modified hyaluronic acid hydrogels for corneal epithelial healing.Bioactive materials · 2023Article
- Artificial Intelligence for Anterior Segment Diseases: A Review of Potential Developments and Clinical Applications.Ophthalmology and therapy · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Impaired corneal wound healing that occurs with ocular surface disease, trauma, systemic disease, or surgical intervention can lead to persistent corneal epithelial defects (PCED), which result in corneal scarring, ulceration, opacification, corneal neovascularization, and, ultimately, visual compromise and vision loss. The current standard of care can include lubricants, ointments, bandage lenses, amniotic membranes, autologous serum eye drops, and corneal transplants. Various inherent problems exist with application and administration of these treatments, which often may not result in a completely healed surface. A topically applicable compound capable of promoting corneal epithelial cell proliferation and/or migration would be ideal to accelerate healing. We hypothesize that human growth hormone (HGH) is such a compound. In a recent study, HGH was shown to activate signal transducer and activators of transcription-5 (STAT5) signaling and promote corneal wound healing by enhancing corneal epithelial migration in a co-culture system of corneal epithelial cells and fibroblasts. These effects require an intact communication between corneal epithelia and fibroblasts. Further, HGH promotes corneal wound healing in a rabbit debridement model, thus demonstrating the effectiveness of HGH in vivo as well. In conclusion, HGH may represent an exciting and effective topical therapeutic to promote corneal wound healing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.